You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Rhinology
On demand events
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
Review the inflammatory endotypes observed in CRSwNP, zooming in on the key role of type 2 cytokines, IL-4, IL-13, and IL-5
Understand the underappreciated burden on health-related quality of life, and the importance of bringing patients into the decision-making process
Define the concepts of statistical significance and clinical importance and the advantages of considering clinically important symptom improvements in patients with CRSwNP
Review evidence of improvements in olfaction with surgery and biologics from real-world effectiveness studies and randomized controlled trials and safety of biologics in patients with CRSwNP
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.